KEY TAKEAWAYS
- The study aimed to investigate the relationship between baseline MTV and survival in patients with NHL undergoing CAR-T therapy.
- Researchers noticed that a high baseline MTV is linked to poorer survival outcomes in NHL following CAR-T therapy.
Chimeric antigen receptor T cell (CAR-T) therapy has emerged as a promising treatment for aggressive Non-Hodgkin lymphoma (NHL).
Lin Liu and the team aimed to explore the relationship between metabolic tumor volume (MTV), as assessed by positron emission tomography prior to CAR-T infusion, and the survival outcomes of patients with NHL.
They performed an inclusive analysis by gathering relevant observational studies related to the purpose of the meta-analysis from PubMed, Web of Science, and Embase, covering data from the inception of these databases to April 1, 2024. The analysis focused on patients with aggressive NHL undergoing CAR-T therapy. Data were synthesized using a random-effects model that accounted for the potential influence of between-study heterogeneity.
About 15 observational studies were included. Pooled results indicated that compared to patients with NHL, a lower MTV and those with a higher MTV before CAR-T infusion were associated with poor progression-free survival (PFS) (hazard ratio [HR]: 1.73, 95% confidence interval [CI]: 1.48 to 2.02, P < 0.001; I² = 20%) and overall survival (HR: 2.11, 95% CI: 1.54 to 2.89, P < 0.001; I² = 58%).
Subgroup analysis revealed that the association between MTV and survival of patients with NHL after CAR-T was not significantly influenced by study design, methods for determining MTV cutoff, or analytic models (univariate or multivariate, P for each subgroup all < 0.05).
The analysis suggested a stronger association between MTV and poor survival outcomes in patients with a median of 2 or 3 lines of previous treatment compared to those with 4 (P for subgroup difference < 0.05). Additionally, meta-regression analyses indicated that the relationship between MTV and survival was not significantly impacted by sample size, age, proportion of men, cutoff value of MTV, follow-up duration, or study quality scores (P all > 0.05).
The study concluded that a high MTV at baseline is linked to poor survival outcomes in patients with NHL following CAR T cell therapy.
The study received no funds.
Source: https://pubmed.ncbi.nlm.nih.gov/39267739/
Liu L, Jin F, Fan H, (2024). “Metabolic tumor volume and the survival of patients with Non-Hodgkin lymphoma treated with chimeric antigen receptor T cell therapy: a meta-analysis.” Front Immunol. 2024;15:1433012. Published 2024 Aug 29. doi:10.3389/fimmu.2024.1433012
